Skip to main content

Table 3 Scoring of GI and GU disorders for WP and PO 3DCRT techniques.

From: The evolution of rectal and urinary toxicity and immune response in prostate cancer patients treated with two three-dimensional conformal radiotherapy techniques

Incidence and development of acute GI/GU toxicity from pretreatment symptoms
   Acute GI toxicity Acute GU toxicity
   WP PO WP PO
Pretreatment
Symptoms
Acute toxicity n % n % n % n %
0 → 0 33 28.45% 40 49.38% 43 37.07% 36 44.44%
0 → 1 14 12.07% 17 20.99% 18 15.52% 12 14.81%
0 → 2 58 50.00% 20 24.69% 25 21.55% 17 20.99%
0 → 3 1 0.86%    1 0.86%   
1 → 0    1 1.23% 13 11.21% 7 8.64%
1 → 1    2 2.47% 6 5.17% 3 3.70%
1 → 2 5 4.31% 1 1.23% 4 3.45% 3 3.70%
1 → 3 2 1.72%       
2 → 0 1 0.86%    1 0.86% 1 1.23%
2 → 1        1 1.23%
2 → 2 1 0.86%    1 0.86%   
2 → 3      2 1.72% 1 1.23%
3 → 0      1 0.86%   
3 → 1         
3 → 2 1 0.72%       
3 → 3      1 0.86%   
Development of late GI/GU toxicity from acute GI/GU toxicity
   GI toxicity GU toxicity
   WP PO WP PO
Acute toxicity Late toxicity n % n % n % n %
0 → 0 29 25.00% 34 41.98% 41 35.34% 31 38.27%
0 → 1 5 4.31% 5 6.17% 13 11.21% 8 9.88%
0 → 2    2 2.47% 1 0.86% 3 3.70%
0 → 3 1 0.86%    3 2.59% 2 2.47%
1 → 0 10 8.62% 11 13.58% 17 14.66% 9 11.11%
1 → 1 4 3.45% 7 8.64% 4 3.45% 2 2.47%
1 → 2      1 0.86% 2 2.47%
1 → 3    1 1.23% 2 1.72% 3 3.70%
2 → 0 47 40.52% 9 11.11% 18 15.52% 10 12.35%
2 → 1 9 7.76% 6 7.41% 8 6.90% 8 9.88%
2 → 2 5 4.31% 5 6.17% 3 2.59% 2 2.47%
2 → 3 2 1.72% 1 1.23% 1 0.86%   
2 → 4 1 0.86%       
3 → 0 2 1.72%       
3 → 1 1 0.86%    2 1.72%   
3 → 2      1 0.86%   
3 → 3      1 0.86% 1 1.23%
Summary of last late GI/GU toxicities dynamics
       WP PO
Last late GI toxicity n % n %
Patients without toxicity 29 25.00% 34 41.98%
Decrease of toxicity (G1,2,3→G0) 59 50.86% 20 24.69%
Patients with moderate toxicity-G1     
   Development G0 → G1 5 4.31% 5 6.17%
   Unchanged grade of toxicity G1 4 3.45% 7 8.64%
   Decrease of toxicity from G2, 3→ G1 10 8.62% 6 7.41%
Patients with high level toxicity G2, 3, 4 9 7.76% 9 11.11%
       WP PO
Last late GU toxicity n % n %
Patients without toxicity 41 35.34% 31 38.27%
Decrease of toxicity (G1,2,3 → G0) 35 30.17% 19 23.46%
Patients with moderate toxicity-G1     
   Development G0 → G1 13 11.21% 8 9.88%
   Unchanged grade of toxicity G1 4 3.45% 2 2.47%
   Decrease of toxicity from G2, 3→G1 10 8.62% 8 9.88%
Patients with high level toxicity G2, 3, 4 13 11.21% 13 16.05%